Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 435-436

  Angelucci, Erika ^a   Cocco, Andrea ^a   Viscido, Angelo ^a   Caprilli, Renzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; HYDROCORTISONE; INFLIXIMAB; MESALAZINE; METRONIDAZOLE;

ADULT; ANAMNESIS; ANOVAGINAL FISTULA; CASE REPORT; CESAREAN SECTION; CLINICAL FEATURE; CONCEPTION; CONGENITAL MALFORMATION; CROHN DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAUTERINE GROWTH RETARDATION; LETTER; MAINTENANCE THERAPY; NEWBORN; NEWBORN DISEASE; PATIENT REFERRAL; PREGNANCY; PREGNANCY OUTCOME; PREMEDICATION; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME; VAGINA DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; RECTOVAGINAL FISTULA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149126742     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20319     Document Type: Letter

References (9)

1. Korelitz BI. Continuing immunomodulators and biologic medications in Pregnant IBD patients - sometimes con. Inflamm Bowel Dis. 2007;13:1441-1442.
2. Fonager K, Sorensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426-2430.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med. 1997;337: 1029-1035.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
5. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFα monoclonal antibody. Hum Exp Toxicol. 2000;19:226-228.
6. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.
7. Lichtenstein G, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4: 621-630.
8. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumor necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:695-698.
9. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738.